Tag: Biotech and Pharma

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street’s expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth.

Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance.

Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company’s Covid vaccine and antiviral pill Paxlovid helped boost sales.

France takes stake in Sanofi unit as part of €16bn sale to CD&R

France is taking a small stake in Sanofi’s consumer healthcare business in order to quell a political backlash, as the pharmaceutical company presses ahead with a €16bn deal that would hand control of the unit to US private equity group Clayton Dubilier & Rice.

Abbott Posts Solid Quarter. That Wasn’t Enough to Lift Shares.

The maker of healthcare products posted adjusted earnings of $1.21 per share for the third quarter, topping Wall Street’s call for $1.20, according to FactSet.

J&J lifts profit and sales forecasts, beats Wall Street expectations

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.

WHO approves Bavarian Nordic’s mpox vaccine for adolescents

The World Health Organization said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

Sanofi in talks to sell 50% stake in consumer health business to CD&R

Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday.

GSK shares jump on $2.2 billion Zantac settlement

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Bayer shares down 7% after U.S. court says it will review Monsanto case

Shares of German life sciences company Bayer fell nearly 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure to products of the company’s Monsanto unit harmed individuals.

Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say

Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter.

FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades

The Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.

Lavipharm: Στα 7,7 εκατ. ευρώ εκτοξεύτηκαν τα ενοποιημένα κερδη μετά από φόρους το εξάμηνο

Αύξηση των ενοποιημένων πωλήσεων παρουσιάζει ο Όμιλος Lavipharm κατά το α’ εξάμηνο του 2024. Συγκεκριμένα, οι ενοποιημένες πωλήσεις από συνεχιζόμενες δραστηριότητες ανήλθαν σε 30,6 εκατ. ευρώ έναντι 29,1 εκατ. ευρώ το αντίστοιχο διάστημα του 2023, σημειώνοντας αύξηση κατά 5,3%.

Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business.

Bavarian Nordic sees potential to ramp up mpox vaccine capacity

Bavarian Nordic said on Thursday it could supply 13 million doses of its mpox vaccine by the end of 2025, up from a previous forecast of 10 million doses, and is exploring options to significantly expand its capacity.

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs

Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids

The drug Liraglutide was shown in a Novo-sponsored late-stage clinical trial to have reduced the body-mass index (BMI) in children aged between 6-11.

AstraZeneca shares fall 5% on disappointing lung cancer drug trial results

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial

Merck  stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a head-to-head trial.

Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine

The World Health Organization earlier this month declared the Mpox outbreak a public-health emergency of international concern. (Dreamstime) were charging higher after the vaccine maker announced the Food and Drug Administration approved its smallpox vaccine for Mpox disease in individuals at high risk for infection.